The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.
Keywords: Astrocytoma; Grade 2 glioma; IDH inhibitor; Oligodendroglioma; Vorasidenib.
Copyright © 2024 Elsevier B.V. All rights reserved.